Found: 5
Select item for more details and to access through your institution.
Evaluation of dried blood spot (DBS) technology versus plasma analysis for the determination of MK-1775 by HILIC-MS/MS in support of clinical studies.
- Published in:
- Analytical & Bioanalytical Chemistry, 2012, v. 404, n. 10, p. 3037, doi. 10.1007/s00216-012-6440-6
- By:
- Publication type:
- Article
Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 1, p. 201, doi. 10.1007/s10637-014-0179-1
- By:
- Publication type:
- Article
A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors.
- Published in:
- 2011
- By:
- Publication type:
- Report
Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial.
- Published in:
- Targeted Oncology, 2021, v. 16, n. 1, p. 47, doi. 10.1007/s11523-020-00767-1
- By:
- Publication type:
- Article